Saracatinib (AZD0530)

For research use only. Not for use in humans.

目录号：S1006 中文名称：塞卡替尼

Saracatinib (AZD0530) Chemical Structure

CAS No. 379231-04-6

Saracatinib (AZD0530)是一种有效的Src抑制剂，无细胞试验中IC50为2.7 nM，对c-Yes， Fyn， Lyn， Blk， Fgr和Lck也具有活性；但对Abl和EGFR (L858R和L861Q)活性较低。Saracatinib可诱导自噬。Phase 2/3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 746.35	现货
10mg	RMB 569.55	现货
200mg	RMB 5472.84	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Saracatinib (AZD0530)发表文献217篇：

Science, 2019, 365(6454)

PubMed: 31320558 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(1):35-49

PubMed: 29249464 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107796

PubMed: 32579923 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):4235-4249e6

PubMed: 32209481 ( click the link to review the publication )

Cell Rep, 2020, 33(7):108398

PubMed: 33207193 ( click the link to review the publication )

Sci Signal, 2020, 13(650)eaba5754

PubMed: 32963013 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):148

PubMed: 32746865 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

J Neurosci, 2020, 40(34):6522-6535

PubMed: 32690613 ( click the link to review the publication )

Cell Death Dis, 2020, 12;11(2):118

PubMed: 32051399 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

PLoS Genet, 2020, 16(3):e1008694

PubMed: 32196488 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):311-320

PubMed: 31832986 ( click the link to review the publication )

J Immunol, 2020, 205(7):1953-1961

PubMed: 32848033 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0186.2020

PubMed: 33004621 ( click the link to review the publication )

Front Oncol, 2020, 3;10:442

PubMed: 32346533 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )
Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Sci Rep, 2020, 9;10(1):4355

PubMed: 32152351 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2020, 10.1152/ajplung.00444.2019

PubMed: 33325804 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.012957

PubMed: 32934005 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:2139-2151

PubMed: 32210580 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0224952

PubMed: 32692785 ( click the link to review the publication )

Neoplasia, 2020, 22(3):129-141

PubMed: 31981897 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):296

PubMed: 30655532 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4349

PubMed: 31554791 ( click the link to review the publication )

J Exp Med, 2019, 216(4):807-830

PubMed: 30819724 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(5):1639-1649

PubMed: 30504425 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3060-3076

PubMed: 31308216 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1311-1322.e5

PubMed: 31665642 ( click the link to review the publication )
J Hematol Oncol, 2019, 12(1):132

PubMed: 31805962 ( click the link to review the publication )

Mol Metab, 2019, 28:36-47

PubMed: 31327757 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0608-1

PubMed: 31649319 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2135-2145

PubMed: 31484705 ( click the link to review the publication )

J Immunol, 2019, 203(11):2990-2999

PubMed: 31619538 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2019, 316(3):C377-C392

PubMed: 30566391 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Dev Comp Immunol, 2019, 96:1-8

PubMed: 30822451 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1911-1917

PubMed: 30628679 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3625-3632

PubMed: 31485668 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(4)e201900425

PubMed: 31331982 ( click the link to review the publication )

Commun Biol, 2019, 2:156

PubMed: 31098401 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5074-5087

PubMed: 31416844 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2068

PubMed: 29802342 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4259

PubMed: 30323235 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 78(4):985-1002.

PubMed: 29279356 ( click the link to review the publication )

Cancer Res, 2018, 78(22):6497-6508

PubMed: 30262461 ( click the link to review the publication )
J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(21):2817-2836

PubMed: 29511352 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):887

PubMed: 30166523 ( click the link to review the publication )

FASEB J, 2018, 32(6):3033-3046

PubMed: 29401603 ( click the link to review the publication )

Neurobiol Dis, 2018, 110:102-121

PubMed: 29197620 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Metallomics, 2018, 10(8):1141-1159

PubMed: 30066004 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Exp Cell Res, 2018, 364(2):208-216

PubMed: 29427623 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

Cancer Med, 2018, 7(2):408-419

PubMed: 29318780 ( click the link to review the publication )

Cancer Med, 2018, 7(3):820-830

PubMed: 29383859 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Viruses, 2018, 10(6)

PubMed: 29795047 ( click the link to review the publication )

Tumour Biol, 2018, 40(8):1010428318794217

PubMed: 30124118 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )
Nat Cell Biol, 2017, 19(2):106-119

PubMed: 28114269 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

J Clin Invest, 2017, 127(4):1338-1352

PubMed: 28240606 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cell Rep, 2017, 20(12):2775-2783

PubMed: 28930674 ( click the link to review the publication )

Cell Rep, 2017, 20(4):999-1015

PubMed: 28746882 ( click the link to review the publication )

Cell Rep, 2017, 21(2):533-545

PubMed: 29020637 ( click the link to review the publication )

Cell Rep, 2017, 18(3):804-815

PubMed: 28099856 ( click the link to review the publication )

Sci Signal, 2017, 10(460)

PubMed: 28049762 ( click the link to review the publication )

J Med Chem, 2017, 60(18):7863-7875

PubMed: 28792760 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

J Virol, 2017, 91(21)

PubMed: 28814523 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

J Cancer, 2017, 8(11):1943-1951

PubMed: 28819393 ( click the link to review the publication )
Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Leuk Res, 2017, 61:44-52

PubMed: 28888102 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Cancer Genet, 2017, 216-217:128-141

PubMed: 29025587 ( click the link to review the publication )

Biotechnol J, 2017, 12(10)

PubMed: 28786556 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103014-103031

PubMed: 29262541 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83872-83889

PubMed: 29137389 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(61-:103014-103031

PubMed: 29262541 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Sci Transl Med, 2016, 8(354):354ra114

PubMed: 27582059 ( click the link to review the publication )

Theranostics, 2016, 6(4):594-609

PubMed: 26941850 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27216177 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra97

PubMed: 27703030 ( click the link to review the publication )

Brain Behav Immun, 2016, 55:236-248

PubMed: 26721416 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2572

PubMed: 28032865 ( click the link to review the publication )

PLoS Genet, 2016, 12(3):e1005931

PubMed: 26978032 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(9):2198-208

PubMed: 27256378 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )
J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Toxicology, 2016, 370:94-105

PubMed: 27693619 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(3):563-570

PubMed: 27666484 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27285768 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Sci Signal, 2015, 8(400):ra106

PubMed: 26508788 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1990

PubMed: 25788415 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2238-48

PubMed: 26208525 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):377-88

PubMed: 25306394 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(12):2687-96

PubMed: 26390252 ( click the link to review the publication )

FEBS J, 2015, 10.1111/febs.13314

PubMed: 25940608 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Pancreas, 2015, 44(1):152-7

PubMed: 25222135 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142219

PubMed: 26556238 ( click the link to review the publication )

Mol Cell Biochem, 2015, 407(1-2):197-207

PubMed: 26045172 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Nature, 2015, 519(7541):57-62

PubMed: 25731159 ( click the link to review the publication )
Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29991-30005

PubMed: 26358373 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9476-87

PubMed: 25823815 ( click the link to review the publication )

Neurotherapeutics, 2015, 12(1):132-42

PubMed: 25549849 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25897-916

PubMed: 26317790 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(5):401-14

PubMed: 24705551 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3003-15

PubMed: 24911146 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4762-71

PubMed: 25023728 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R45

PubMed: 24887236 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-38

PubMed: 24482380 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

J Chem Inf Model, 2014, 54(3):881-93

PubMed: 24490903 ( click the link to review the publication )

Ultrasound Med Biol, 2014, 40(6):1177-86

PubMed: 24612644 ( click the link to review the publication )

Placenta, 2014, 35(10):824-30

PubMed: 25108485 ( click the link to review the publication )

Oncotarget, 2014, 6(3)

PubMed: 25596741 ( click the link to review the publication )

University of Manche, 2014, aus Landshut

PubMed: ( click the link to review the publication )

J Neurooncol, 2014, 120(1):33-41

PubMed: 25048528 ( click the link to review the publication )

Oncotarget, 2014, 5(19):8853-68

PubMed: 25326682 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )
Pac Symp Biocomput, 2014, 2014:125-35

PubMed: 24297540 ( click the link to review the publication )

Dissertation zur Erlangung des Doktorgrades, 2014,

PubMed: ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Cell Biol, 2013, 15(4):395-405

PubMed: 23455479 ( click the link to review the publication )

Blood, 2013, 122(7):1203-13

PubMed: 23836556 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2037-48

PubMed: 23543053 ( click the link to review the publication )

Int J Cancer, 2013, 132(1):224-35

PubMed: 22623106 ( click the link to review the publication )

Breast Cancer Res, 2013,

PubMed: 24044505 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e915

PubMed: 24201814 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2013, 1829(10):1147-59

PubMed: 23948603 ( click the link to review the publication )

Mol Carcinog, 2013, 10.1002/mc.22092

PubMed: 24127286 ( click the link to review the publication )

PLoS One, 2013, 8(4):e60889

PubMed: 23593342 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Res, 2011, 71(24):7547-57

PubMed: 21994334 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(3):249-58

PubMed: 21296861 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )
Mol Endocrinol, 2010, 24(6):1151-64

PubMed: 20371703 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

特性

Saracatinib是第一个作用于人类肿瘤组织Src通路的抑制剂。

靶点

c-Src ^[2] (Cell-free assay)	LCK ^[2] (Cell-free assay)	c-YES ^[2] (Cell-free assay)	EGFR (L861Q) ^[2] (Cell-free assay)	Lyn ^[2] (Cell-free assay)	点击更多
2.7 nM	<4 nM	4 nM	4 nM	5 nM	点击更多

体外研究

Saracatinib也有效抑制其他Src酪氨酸激酶家族成员，包括c-Yes, Fyn, Lyn, Blk, Fgr, 和Lck，IC50为4到10 nM。Saracatinib有效抑制SrcY530F突变的NIH 3T3细胞，IC50为80 nM。在NBT-II膀胱癌细胞中，Saracatinib显著阻断HT1080细胞通过立体骨胶原基质的入侵，且完全抑制EGF诱导的细胞分散。^[1]Saracatinib作用于DU145和PC3细胞，通过抑制Y419磷酸化而有效抑制Src激活。Saracatinib抑制前列腺癌包括PC3, DU145, CWR22Rv1和 LNCaP的生长，而Saracatinib作用于 LAPC-4, PZ-HPV7和RWPE-1细胞时却显示低活性。Saracatinib使细胞周期停止在G1/S期，但是不使caspase 3断裂。Saracatinib 也明显抑制Boyden 小室的DU145和PC3 移动。^[2]Saracatinib有效且持久抑制Akt，且增强A549和Calu-6细胞对放射处理的敏感性。^[3]Saracatinib在活性，再吸收，及组成上抑制蚀骨细胞。Saracatinib也可逆阻断蚀骨细胞前体的移动。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CTV-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHOzVVFKSzVyPUCuNFYyPDNizszN	M4ewO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LAMA-84	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkDnTWM2OD1yLkG1PVkh\|ryP	MkC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MEG-01	NWrLc5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX7BT2l5UUN3ME2wMlI{Pjh6IN88US=>	NFLwO2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
EM-2	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1jmd2lEPTB;MD6yOlUh\|ryP	NIrMU3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-15	NUe0OWF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmLJTWM2OD1yLkK3OFEzKM7:TR?=	M1XiW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H1648	NYfqU3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnnkTWM2OD1yLkK4NVE3KM7:TR?=	NEfXU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-12	M1LYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnnZTWM2OD1yLkOyOlgh\|ryP	NFrpVmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LB996-RCC	MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmfITWM2OD1yLkS0NVk3KM7:TR?=	MofnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
K-562	M{XGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXnJR\|UxRTBwNES5Olch\|ryP	MnTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
D-336MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX\JR\|UxRTBwNUCzNFQh\|ryP	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NOS-1	M3vPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVL3VnRPUUN3ME2wMlYxPTJ7IN88US=>	NETiTZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
EW-24	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoHpTWM2OD1yLk[yOlk{KM7:TR?=	NE\HelI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BV-173	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2\BZmlEPTB;MD62OVI1QSEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCCIT	NHjn[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnLyTWM2OD1yLkezNlE5KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H1436	M3LCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoS5TWM2OD1yLke5NFQ6KM7:TR?=	NF3HdnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BB30-HNC	M3fx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF\nOXhKSzVyPUCuPFYzODNizszN	NInTb3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-8	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWTJR\|UxRTBwOEeyO\|Uh\|ryP	MnTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
A704	NUCwO4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3vjTGlEPTB;MD64PVIyKM7:TR?=	MoHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TK10	NVTiXlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnzCTWM2OD1yLkmwOlY6KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KS-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH;ubW1KSzVyPUGuNVk4PzlizszN	M13NPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
C2BBe1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4\GOWlEPTB;MT6yNFUxPyEQvF2=	M4nxeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RXF393	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MojYTWM2OD1zLkK0N\|Yh\|ryP	NWT6Z5JNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KGN	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoXhTWM2OD1zLkK3Olg4KM7:TR?=	M1H2T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB69	MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHWy[oRKSzVyPUGuN\|c1QTdizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-11	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MljDTWM2OD1zLkSzOFE5KM7:TR?=	MmTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-1	NIO5cGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlL5TWM2OD1zLkS0NVA2KM7:TR?=	NYfPc5hyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
ST486	MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml3STWM2OD1zLkS1PFUzKM7:TR?=	M1fYdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HOP-62	NFrrNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYDV[WtjUUN3ME2xMlUxOjR4IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EW-16	NU\hW4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MojqTWM2OD1zLkW1NFg{KM7:TR?=	M1vZSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LB1047-RCC	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHHpe41KSzVyPUGuOVU1PTNizszN	NW\BZYFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-10	NV\XeZdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHfqVlVKSzVyPUGuOlYzPTJizszN	NXjoS5ZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
RL95-2	M13XNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmrQTWM2OD1zLk[2PVAzKM7:TR?=	Mk\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
DOHH-2	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mny3TWM2OD1zLkexO\|gzKM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MFH-ino	NEmx[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoHSTWM2OD1zLke3PFch\|ryP	NHn3Rog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
GB-1	M2T3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVjJR\|UxRTFwN{m4N\|Mh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SK-N-DZ	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUHjdHF6UUN3ME2xMlg1Pjh6IN88US=>	NVLLdZFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
OS-RC-2	NGO4OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVXJR\|UxRTFwOEi1O\|Qh\|ryP	NUjySGh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SW982	NWfEcoF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{nKemlEPTB;MT65NlA6OyEQvF2=	NUDWPXU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KALS-1	NYrQNnZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHPDNIpKSzVyPUGuPVg4OjJizszN	MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX\mW5FZUUN3ME2yMlA2QTV6IN88US=>	NHu2cHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
GI-1	M3WyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXPveY1TUUN3ME2yMlE3ODh2IN88US=>	MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW962	M3LiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF75W\|VKSzVyPUKuNVcyPzhizszN	NWW5XYE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SW872	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVrINppFUUN3ME2yMlE5PTB5IN88US=>	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H747	M1S5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MY\JR\|UxRTJwMkW3NVQh\|ryP	MnLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MZ1-PC	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVXDNpA4UUN3ME2yMlI6OzV4IN88US=>	M{[5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MSTO-211H	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEf5VnJKSzVyPUKuN\|U4OjNizszN	M{PLblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BL-70	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1fhNmlEPTB;Mj60O\|QzOiEQvF2=	NITGUpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SW954	M{PldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1Hwc2lEPTB;Mj61O\|QxQCEQvF2=	MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SNB75	NGPBVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3G0SGlEPTB;Mj62PFU6PCEQvF2=	M2TXOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
IST-SL2	M{fudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV\JR\|UxRTJwN{KzO\|kh\|ryP	NF\WSGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
GCIY	NFLwT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mnq1TWM2OD1{Lki3NFA2KM7:TR?=	NYTYOW1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KU812	NFT3eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUnMTYZYUUN3ME2zMlA2Ojl7IN88US=>	NEXqRmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LXF-289	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYDJR\|UxRTNwMUKxNFkh\|ryP	M{PBSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ETK-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEHKWZRKSzVyPUOuNlA4PjdizszN	M3;NZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SF126	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTiTWM2OD1\|LkOxNVc1KM7:TR?=	NGD3cW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LC-2-ad	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYXIRZpwUUN3ME2zMlU2PyEQvF2=	NVz5WVR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KNS-42	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGnFXJRKSzVyPUOuOlUh\|ryP	NVXoTGJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
OVCAR-4	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV3W[odnUUN3ME2zMlc{PDN\|IN88US=>	MoO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
PF-382	M1jj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV\0cIR{UUN3ME2zMlg{Pjl6IN88US=>	NHzZXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SH-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mkm0TWM2OD12LkK1NlU6KM7:TR?=	NFP0d2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KM12	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX\lVXNiUUN3ME20MlMzPDF4IN88US=>	NVPOXIdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NB5	M2PYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2fBVWlEPTB;ND60NVg3PCEQvF2=	NXL2SnNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KURAMOCHI	NYTTPIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTVN\|lLUUN3ME20MlY2OjV4IN88US=>	NIK5Tm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
Becker	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3XGWWlEPTB;ND62OlQyPiEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MV-4-11	NVz0fHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlLVTWM2OD12LkixN\|Q1KM7:TR?=	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KINGS-1	M33Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3q3cmlEPTB;ND64NlM4OyEQvF2=	M1HQdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LS-123	NVO2WYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIHGNJpKSzVyPUWuOFk3QDRizszN	NXG2PHBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SF268	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVXJR\|UxRTVwNkGyOlIh\|ryP	MljlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
A388	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlLxTWM2OD13Lk[zOlY4KM7:TR?=	NIX3R289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NMC-G1	NFHjXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmHwTWM2OD14LkCxPFEyKM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CGTH-W-1	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmXTTWM2OD14LkCyNFc2KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ES4	NGrv[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFTBOoZKSzVyPU[uOVMxPzRizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SR	NILIeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVrJR\|UxRTZwNUi4NFch\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BB49-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF7jNHNKSzVyPU[uO\|MzODZizszN	NHe5XVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KLE	M3T4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3XvXmlEPTB;Nj63PFM4PyEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HUTU-80	NUfETGVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnviTWM2OD14Lkm4OFY3KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SNU-C2B	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIf5enhKSzVyPUeuPFI4OzdizszN	M1riUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BB65-RCC	NVi4RoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4jX[GlEPTB;Nz65OFkxPCEQvF2=	M1TJT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
QIMR-WIL	M1uxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXPJR\|UxRThwNEK4NFgh\|ryP	NYXFdoNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GDM-1	M2G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{i0VmlEPTB;OD65O\|I6OiEQvF2=	NWDqW\|V2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LC4-1	MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml7LTWM2OD17LkCwPVEyKM7:TR?=	NYHucFBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MLMA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVr6V2tXUUN3ME25MlE2ODB4IN88US=>	NEK0OFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
EoL-1-cell	NH7RSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTlwM{CxPVIh\|ryP	NIft[Yk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BOKU	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYfJR\|UxRTlwOU[0OlYh\|ryP	NFW0d3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
EVSA-T	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVnJR\|UxRTFyLk[1Olgh\|ryP	NFLpTJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
D-283MED	M2DxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVPJR\|UxRTFyLkmxO\|Yh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB1	NWHnOmcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUfJR\|UxRTFzLkCyOFIh\|ryP	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
RPMI-8402	NYTQSIwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkT4TWM2OD1zMT6xO\|gh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H1355	M2CzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MULJR\|UxRTFzLkG4NFYh\|ryP	MkLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NB7	NVrETI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlPLTWM2OD1zMT6zNlk4KM7:TR?=	MmPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
RPMI-6666	NFTr[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{nrbWlEPTB;MUKuPVU3PyEQvF2=	NYPvWoVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
697	NGfDb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYrCbGV[UUN3ME2xN{4zPzBzIN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CTB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIq2fFFKSzVyPUGzMlU6PDhizszN	NYfndIxZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4rTWGlEPTB;MUOuPVI{PCEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BE-13	NFjCd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVrrV5dRUUN3ME2xOE4{QTF3IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SKM-1	M1LKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUnJR\|UxRTF2LkS0PVkh\|ryP	MonXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXXKW2F6UUN3ME2xOE44PTlzIN88US=>	NUX6SlVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB771-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVL0N2VqUUN3ME2xOE44QDl6IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ECC4	M{Lwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF7mWmpKSzVyPUG3MlAzPzdizszN	M2K0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ES3	M2Ta[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4\VN2lEPTB;MUeuOFY2PSEQvF2=	M2jqO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LB647-SCLC	M3e3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIfhZlFKSzVyPUG3MlQ6PDlizszN	MmTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NB10	NF7lbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWPJR\|UxRTF6LkWyOVYh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
L-540	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmPzTWM2OD1zOD64NVA6KM7:TR?=	NGm0S3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NCI-H2126	NXjUV\|lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4fRTWlEPTB;MUmuOVEh\|ryP	NWHGV2U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
HH	M3fTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXrJR\|UxRTJyLkCwPVkh\|ryP	Ml7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MPP-89	M{\JPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXHJR\|UxRTJ\|LkKyPFkh\|ryP	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
IST-MEL1	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml35TWM2OD1{Mz64OlU5KM7:TR?=	NIf6TGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KP-N-YS	NWTPRmV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH\pV4JKSzVyPUKzMlkzPTVizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EC-GI-10	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{K3fmlEPTB;MkSuOVk5QSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EKVX	NHvKNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2Tj[GlEPTB;Mk[uNFIxOyEQvF2=	MkTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TGBC1TKB	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M37NcWlEPTB;Mk[uOFM1KM7:TR?=	M3PCOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
Daudi	NGGw[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXie\|FRUUN3ME2yO{4xPzd\|IN88US=>	NUD0S3BwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
ALL-PO	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWPTcFQ1UUN3ME2yO{4xQDFizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB6	NUnScJAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MofrTWM2OD1{Nz60PFgh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ES6	M1\YcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVTlXJdRUUN3ME2yO{46OTJ\|IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfyTWM2OD1{OD6wN\|c{KM7:TR?=	M4XiZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
K5	M4Ps[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUizU5ZZUUN3ME2yPE4yOjh5IN88US=>	MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ES1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVPJR\|UxRTJ6Lke3O\|Mh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LC-1F	M2j5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MontTWM2OD1{OT63N\|Q3KM7:TR?=	MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SCLC-21H	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFnze2NKSzVyPUOwMlc{OTdizszN	MlqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	NFjaVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGPjN45KSzVyPUOyMlU2QThizszN	MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
D-247MG	NUPQOXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVHJR\|UxRTN{Lkm3O\|Mh\|ryP	NYSwcVI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-5	NE\pO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoTQTWM2OD1\|Mz6wN\|YzKM7:TR?=	NHO3NXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
MONO-MAC-6	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWnJR\|UxRTN\|LkWwOFgh\|ryP	NV\UNllkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	NW\kW3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4\CcGlEPTB;M{OuO\|Y3PiEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LOXIMVI	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUHxO5ljUUN3ME2zN{44QTJ6IN88US=>	NYjIWYQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCI-H209	NH\OS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3zrRmlEPTB;M{WuNVQ1KM7:TR?=	NXO4OJlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
A253	NXO0SWdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NE\Kc41KSzVyPUO1Mlc1OjlizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HCC1599	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUL3Z2ZyUUN3ME2zOk44ODV\|IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EB-3	M3nSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGTSRXZKSzVyPUO2Mlk2OThizszN	NUftWIRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GOTO	NXfZbmxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnixTWM2OD1\|Nz6zNlI1KM7:TR?=	NVvRb\|BnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SW684	NFqyTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXvFSnZ5UUN3ME20NU45PDl3IN88US=>	MmPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
DEL	M1LPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYq4dJg2UUN3ME20Nk4xPTJ{IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HT-144	NF\SOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGC5V4VKSzVyPUSyMlE3PzZizszN	MlX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-9	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXjJR\|UxRTR\|LkS1PVYh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KARPAS-45	M1;1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1TRVGlEPTB;NESuN\|kzPSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HAL-01	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXHJR\|UxRTR2LkWwN\|Qh\|ryP	Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
RCC10RGB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M33U[WlEPTB;NESuO\|M6OiEQvF2=	NF7yZVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
CP67-MEL	NYfWOHFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH3MdotKSzVyPUS1MlYzPDFizszN	Mn:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NB17	NEjHeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnLxTWM2OD12NT62OlQ{KM7:TR?=	MoC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SK-UT-1	NW\1S5MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoDiTWM2OD12NT65OFY1KM7:TR?=	NYTPVHdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003	M17BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3nYXWlEPTB;NE[uNFEyQSEQvF2=	M1rSXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HCE-4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkTGTWM2OD12Nj61PVY5KM7:TR?=	M{nOd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H720	M4HtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1nkNWlEPTB;NE[uO\|Y5OiEQvF2=	NWDXSIdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KARPAS-422	M3zKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYm3eIs{UUN3ME20O{4xQDl3IN88US=>	NUDqdHF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHznO5FKSzVyPUS3MlE3OjJizszN	MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HCE-T	M4jRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGK2ZplKSzVyPUS3MlY5OjhizszN	MojkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
PSN1	M4TxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHvRPZVKSzVyPUS3Mlc5OTNizszN	MoLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NIH3T3	NITmVo1HfW6ldHnvckBie3OjeR?=			M3LDUWlvcGmkaYTpc44hd2ZiaIXtZY4h[y2VcnOgbY4hVkmKM2SzJINmdGy\|LDDJR\|UxKD1iMD6wNFI4KM7:TT6=	M{fuVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5ME[0NFY3Lz5zN{C2OFA3PjxxYU6=
HEK293	MmfkSpVv[3Srb36gZZN{[Xl?		MV6xJIhz	M3jKZ2lvcGmkaYTpc44hd2ZiaIXtZY4h\nWubDDs[Y5ofGhiUFvNXXQyKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMhfXOrbnegSWZUKCh{NEegeI8hOjV7IILld4llfWW\|KTDhd{B{fWK\|dILheIUh[W[2ZYKgNUBpeiCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHntcZVvd2G\|YYmsJGtqKD1iMD6wN\|k5KM7:TT6=	MkfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEGxPVMoRjJ7OUSxNVk{RC:jPh?=
HEK293	MVXGeY5kfGmxbjDhd5NigQ>?		MUmxJIhz	M1XvSGlvcGmkaYTpc44hd2ZiaIXtZY4h\nWubDDs[Y5ofGhiUFvNXXQyKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMhfXOrbnegSWZUKCh{NEegeI8hOjV7IILld4llfWW\|KTDhd{B{fWK\|dILheIUh[W[2ZYKgNUBpeiCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHntcZVvd2G\|YYmsJGlEPTBiPTCwMlQyQCEQvF2u	NUPkNodzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl\|PD;hQi=>
Rh30	M{TKdmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEnINVA1QCCqcoO=	M3PUeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUnizNEBk\WyuczDh[pRmeiB2ODDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhUUN3MDC9JFExNjFizszNMi=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6N{C5PUc,OjN5OEewPVk9N2F-
Huh7	NXTC[2VtSW62aY\pdoFtKGG\|c3H5	NHO5TmgzNjVidV2=	M1viZ\|Uh\GG7cx?=	NIriTXdKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgbJVu[W5iSIXoO{Bk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VSCjZoTldkA2KGSjeYOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4w>	NIjDTog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
Huh7	MYfBcpRqfmm{YXygZZN{[Xl?	NHT0OIwzNjVidV2=	M3fpVVYh\GG7cx?=	Mk[2TY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOkBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	NWXIUYJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
Vero	NVz0V4drSW62aY\pdoFtKGG\|c3H5	NGW5T5czNjVidV2=	M17oS\|Qh\GG7cx?=	NHuwPJlKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC0JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
Vero	M2HVV2FvfGm4aYLhcEBie3OjeR?=	NX76eJpGOi53IIXN	MXm2JIRigXN?	MUjJcohq[mm2aX;uJI9nKH[rcnHsJJNxemWjZDDpckBF\W6pdXWgeolzfXNvaX7m[YN1\WRiYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TTDh[pRmeiB4IHThfZMh[nliaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2x?	M4Xx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
C6/36	NE\YUG1CdnSrdnnyZYwh[XO\|YYm=	MlfNNk42KHWP	NELPUlg1KGSjeYO=	MV7Jcohq[mm2aX;uJI9nKH[rcnHsJJNxemWjZDDpckBF\W6pdXWgeolzfXNvaX7m[YN1\WRiYYPpZY4hfGmpZYKgcY9{eXWrdH:gR\|YwOzZiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2gZYZ1\XJiNDDkZZl{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u	MonTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
C6/36	M1u2WmFvfGm4aYLhcEBie3OjeR?=	NH7hbYIzNjVidV2=	MnrrOUBl[Xm\|	MlPQTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHHzbYFvKHSrZ3XyJI1we3G3aYTvJGM3NzN4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXNJIFnfGW{IEWg[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	NYrreVQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
Vero	NELXUpFCdnSrdnnyZYwh[XO\|YYm=		M2rCU\|Mh\GG7cx?=	NWLKVItYSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhTGWwZ4XlJJZqenW\|IHnu[oVkfGWmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYXTtbY5qe3SncnXkJIFnfGW{II\pdoFtKGOqYXzs[Y5o\SCjZoTldkA{KGSjeYOgZpkhfmm{YXygdIxieXWnIHHzd4F6	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
Vero	MX\BcpRqfmm{YXygZZN{[Xl?	NX64RZJ[Oi53IIXN	NHP2Xos2KGSjeYO=	Mn3FTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u	NXTafGR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
Huh7	NYe2cXozSW62aY\pdoFtKGG\|c3H5	NYfZSpFGOi53IIXN	MnjEOEBl[Xm\|	M1KzUWlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDoeY1idiCKdXi3JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFQh\GG7czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
C6/36	M1HLXmFvfGm4aYLhcEBie3OjeR?=	NUHJXIdUOi53IIXN	MnfxOkBl[Xm\|	NGWwfXRKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZZNq[W5idHnn[ZIhdW:\|cYXpeI8hSzZxM{[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOkBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
HEK293	NXrW[m42TnWwY4Tpc44h[XO\|YYm=	NFmy[WsxNjFidH:gNUB2VQ>?	MmHBNVYhcHK\|	MlHXTY5pcWKrdHnvckBw\iClb3zsZYdmdiCLLXnu[JVk\WRiRFTSNkApfW6tbn;3ckBwemmpaX6pJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHH0JFAvOSC2bzCxJJVOKGGodHXyJFE3KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7n	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF7MUO2PUc,OjZzOUGzOlk9N2F-
A673	NHzIcWVyUFSVIHHzd4F6			M1\m[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	M2TLOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	M{P1SZFJXFNiYYPzZZk>			MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MV\xTHRUKGG\|c3H5			NX7VV2xjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NVvkVnJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MVzxTHRUKGG\|c3H5			NEniZWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	NVvRTZZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NHPtcHFyUFSVIHHzd4F6			M2ryT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NIjlR2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NVm1SlRUeUiWUzDhd5NigQ>?			NYi0TmQzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NX;PZZZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	M3TzVJFJXFNiYYPzZZk>			NGPUWYRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NU\mWGpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MXXxTHRUKGG\|c3H5			M2\nRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	Mn\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MoK4dWhVWyCjc4PhfS=>			NWXQeppveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MoXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HEK293	NXrDe2dzTnWwY4Tpc44h[XO\|YYm=	MYqwMlEhfG9iMTD1US=>	MkDWNVYhcHK\|	MYjJcohq[mm2aX;uJI9nKGOxbHzh[4VvKElvaX7keYNm\CCGRGKyJGk3OziIIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHCqb4PwbI9zgWyjdHnvckBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF1KDBwMTD0c{AyKHWPIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5o	NX\JeW1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVE{PjlpPkK2NVkyOzZ7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pY576-FAK / pY861-FAK / FAK; PubMed: 20551056 Cancer Res (A) HCT116 (left) and WiDr (right) cells were exposed to the indicated concentrations of saracatinib for 24 hours and the effect on total FAK or FAK phosphorylation on tyrosine 576 or 861 was assessed by western blotting. Result is representative of three independent experiments. pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin; PubMed: 20505783 J Cancer Sci Ther Saracatinib inhibits Src activity and downstream Src substrate phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with DMSO vehicle or saracatinib (0.01–1 μM) for 24 h. Cells were lysed and total protein amounts were analyzed by Western blotting with total or phosphorylation site-specific antibodies for Src and the indicated substrates. Blots shown are representative of at least four independent experiments, with band intensities for each substrate quantified relative to the untreated (0 μM) condition for each cell line. p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα; PubMed: 20811583 Genes Cancer PC3 cells were treated with 10 μM PP2 (left panel)/1 μM saracatinib (right panel) for 0.5, 1, 2, 4, 8, and 24 h. Cell lysates were analyzed by immunoblotting with antibodies as indicated. Controls were treated with vehicle alone. β-actin was detected as loading control.	20551056 20505783 20811583
Growth inhibition assay	Cell number; PubMed: 24349321 PLoS One LNCaP 104-S, 104-R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of Saracatinib for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p <0.001 between the treated group and the control group.	24349321

体内研究

Saracatinib作用于Src3T3异体移植物显示出强的肿瘤生长抑制率，且Saracatinib造成Calu-6, MDA-MB-231, AsPc-1和BT474C移植瘤生长适当延迟。^[1]Saracatinib处理常位DU145鼠，按鼠体重，每千克每天口服处理25mg Saracatinib，结果显示出强的抗癌活性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 使用受体和非受体酪氨酸激酶的重组催化区，通过酶联免疫吸附法测定酪氨酸激酶活性的IC50值。加入的Saracatinib剂量从0.001到10 mM不等。针对丝氨酸/苏氨酸激酶的特定实验是加³²P 的渗透捕捉实验。在加入10 μL 20mM Mg.ATP开始反应前，包含0.5 μL Saracatinib或DMSO（作对照) 或pH 3.0 buffer（作对照）的多支路384孔板加入15 μL酶和肽/蛋白底物温育5分钟。所有酶的最终浓度都接近米氏常数（K_m）。实验在室温下进行30分钟，然后加入5 μL正磷酸终止反应。混合后，孔中的内含物加到P81联合板上，使用正磷酸作为洗涤缓冲液，然后计算IC50值。
细胞实验： ^[2]	- 合并 Cell lines: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7，和RWPE-1细胞 Concentrations: 62.5 nM-16 mM Incubation Time: 1, 3，和5天 Method: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 及RWPE-1细胞按2×10³密度接种在96孔板上，温育过夜。加入浓度不等（62.5 nM-16 mM）的Saracatinib。1,3,5天后分离培养基，每孔加入0.2 mL DMSO，按每分钟200轮持续震荡96孔板15分钟。MTT实验测IC50值。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 移植DU145细胞的CB17鼠 Dosages: 25 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	35 mg/mL warmed (64.57 mM)
	Ethanol	31 mg/mL (57.19 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Saracatinib (AZD0530) SDF

分子量	542.03
化学式	C₂₇H₃₂ClN₅O₅
CAS号	379231-04-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04598919	Recruiting	Drug: Saracatinab\|Drug: Placebo	Idiopathic Pulmonary Fibrosis (IPF)	National Jewish Health\|Yale University\|Icahn School of Medicine at Mount Sinai\|AstraZeneca\|National Center for Advancing Translational Science (NCATS)	November 12 2020	Phase 1\|Phase 2
NCT04307953	Recruiting	Drug: AZD0530 Difumarate\|Drug: Matching placebo	Fibrodysplasia Ossificans Progressiva	VU University Medical Center\|Royal National Orthopaedic Hospital NHS Trust\|Klinikum Garmisch-Patenkirchen\|University of Oxford\|Brigham and Women''s Hospital\|AstraZeneca\|Innovative Medicines Initiative	August 5 2020	Phase 2
NCT02085603	Completed	Drug: Saracatinib\|Drug: Placebo	Cancer	Sheffield Teaching Hospitals NHS Foundation Trust\|AstraZeneca	March 2014	Phase 2
NCT01864655	Completed	Drug: saracatinib\|Drug: Placebo	Alzheimer''s Disease	Stephen M. Strittmatter\|Yale University	July 2013	Phase 1
NCT01000896	Withdrawn	Drug: AZD0530\|Drug: Carboplatin\|Drug: paclitaxel	Cancer\|Non Small Cell Lung Cancer\|Epithelial Ovarian Cancer	AstraZeneca	January 2010	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the half-life of Saracatinib?
回答：
Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Src Signaling Pathway Map

Src Inhibitors with Unique Features

活性最高的Src抑制剂

Dasatinib : Src, IC50=0.8 nM.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

定制您的化合物库

Saracatinib (AZD0530)

客户使用Selleck生产的Saracatinib (AZD0530)发表文献217篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Saracatinib (AZD0530) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品